Yes, Medicare covers transcranial magnetic stimulation (TMS) for treatment-resistant major depressive disorder when specific documentation and trial requirements are met. Coverage is not automatic or universal: it depends on your diagnosis, prior treatment history, the setting where TMS is delivered, and how the provider bills. Medicare Advantage plans must cover at least what Original Medicare covers, but they can add prior authorization layers that delay or deny care.
TMS is a noninvasive brain stimulation technique that uses pulsed magnetic fields to modulate cortical excitability. The question of Medicare coverage matters because TMS is expensive, repetitive, and time-intensive, and patients often discover the billing rules only after a referral. This explainer walks through the mechanism, the coverage thresholds, the edge cases that trip people up, and the practical steps that determine whether a claim is paid.
How TMS works at the circuit level
TMS delivers brief, high-intensity magnetic pulses through a coil placed against the scalp. The magnetic field passes through the skull without significant attenuation and induces an electric current in the underlying cortex. That current depolarizes neurons in a targeted region, most commonly the left dorsolateral prefrontal cortex for depression.
The mechanism is not simple stimulation of a "depression center." The dorsolateral prefrontal cortex participates in cognitive control and emotional regulation, and it is connected to limbic structures involved in mood. Repetitive TMS (rTMS) alters synaptic strength over repeated sessions, a process resembling long-term potentiation and long-term depression. Functional imaging shows changed activity in frontal and limbic circuits after a treatment course, not just at the stimulation site.
One layer deeper: the pulse frequency and coil orientation determine whether cortical excitability rises or falls. High-frequency stimulation tends to increase excitability in the target region; low-frequency stimulation tends to decrease it. This is why protocol selection is a clinical decision, not a billing formality. The same machine can produce opposite physiological effects depending on how it is programmed.
A plain-language version: TMS uses magnetism to nudge specific brain circuits into a different pattern of activity, and the pattern depends on how the pulses are configured.
What Medicare actually covers and the numbers behind it
Original Medicare (Part B) covers TMS for major depressive disorder when patients have failed to respond to prior antidepressant treatment. The coverage framework rests on National Coverage Determination 160.24, which established that TMS is reasonable and necessary only for a defined clinical population. That determination limits coverage to specific diagnostic and treatment-history criteria rather than approving TMS for any depressive episode.
The clinical threshold that matters most is treatment resistance. Coverage generally requires failure of at least one adequate antidepressant trial, and many Medicare Administrative Contractors apply stricter local rules requiring multiple failed trials. An "adequate trial" usually means a therapeutic dose taken for a sufficient duration, commonly six to eight weeks or more. A patient who stopped a medication after ten days because of side effects may not meet the threshold, even though the experience was real.
Session counts follow the evidence base. Acute treatment typically involves daily sessions over four to six weeks, often around 20 to 30 sessions, followed by a taper. Maintenance TMS is a separate question; coverage for ongoing maintenance is narrower and varies by contractor, so patients should not assume the acute course extends indefinitely.
Payment is bundled. Medicare pays for the treatment session under a single code that includes the physician's supervision, the device operation, and clinical management during treatment. The coil, the machine, and the room are not separately billable to the patient in the way an imaging scan would be. That bundling matters because it shapes which settings offer TMS: hospital outpatient departments, physician offices, and freestanding clinics each have different economics.
The counterintuitive detail: a device being FDA-cleared does not mean Medicare covers every use. FDA clearance establishes that a device is safe and effective for its labeled indication; Medicare coverage additionally requires that the use be reasonable and necessary for the Medicare population. Those are separate gates, and passing one does not guarantee passing the other.
Where coverage breaks down: edge cases
Diagnosis is the first failure point. Medicare's coverage is tied to major depressive disorder, not to bipolar depression, not to anxiety as a standalone indication, and not to off-label uses such as chronic pain or tinnitus. A patient with bipolar disorder and a depressive episode may not qualify under the national determination even though TMS can be used clinically in other contexts.
Setting is the second failure point. Hospital outpatient departments, physician offices, and community clinics bill differently, and some contractors impose site-specific documentation requirements. A clinic that offers TMS may be out of network or may not accept assignment, which shifts cost to the patient.
Documentation is the third failure point. Claims are denied when the record does not show the required prior medication trials, the dates and doses of those trials, the validated symptom scores before and after treatment, or the treating physician's order. Medicare contractors audit these records, and a denial can surface months after treatment.
Medicare Advantage adds a fourth layer. Plans must cover the same services as Original Medicare but often require prior authorization before the first session and sometimes before continuation. Authorization approval is not a guarantee of payment if the documentation does not match the approved request.
Red flags to watch for:
A clinic that guarantees coverage before reviewing your medication history and diagnosis. A request to pay upfront for the full course with a promise of later reimbursement. Prior authorization approved for a different diagnosis than the one documented in your chart. No written treatment plan specifying session count, target, and outcome measures. Pressure to skip the required prior medication trials to "get started faster."
Misconceptions that cost patients money
The most common misconception is that FDA clearance equals Medicare coverage. It does not, and the gap between the two is where most surprises occur.
The second is that a referral from a psychiatrist guarantees payment. A referral establishes medical appropriateness; it does not satisfy the contractor's documentation rules or prior authorization requirements.
The third is that TMS is covered for any depression that has not improved. Medicare's threshold is treatment-resistant major depressive disorder with documented adequate trials, not simply persistent low mood.
The fourth is that Medicare Advantage and Original Medicare behave identically. The coverage floor is the same, but the administrative path is not, and prior authorization can delay treatment by days or weeks.
The fifth is that maintenance sessions are routinely covered. Coverage for maintenance TMS is limited and contractor-dependent, and the evidence base for long-term maintenance is less settled than for the acute course.
Comparison of treatment options and coverage posture
| Option | Invasive? | Typical course | Medicare coverage posture |
|---|---|---|---|
| Repetitive TMS (rTMS) | No | Daily sessions over 4-6 weeks | Covered for treatment-resistant MDD with documentation |
| Deep TMS (H-coil) | No | Similar daily course | Covered when the same criteria are met; contractor rules vary |
| Electroconvulsive therapy (ECT) | Yes, anesthesia | Usually 6-12 sessions | Covered for severe or treatment-resistant depression |
| Ketamine/esketamine | Yes, IV or nasal | Induction then maintenance | Covered under specific conditions and settings |
| Psychotherapy alone | No | Weekly, months | Covered; often insufficient alone for severe MDD |
| Antidepressant trial | No | 6-8 weeks at therapeutic dose | Covered; a prerequisite for TMS coverage |
Practical steps that determine whether a claim is paid
Start with the diagnosis in writing. Ask your treating clinician to document major depressive disorder and the specific prior medication trials, including drug name, dose, duration, and outcome. A trial that was stopped early for side effects should be described as such rather than counted as an adequate trial.
Confirm the setting and network status. Call the clinic and ask three questions: Do you accept Original Medicare or my Medicare Advantage plan? Do you require prior authorization for TMS? Who handles the authorization and what documents do they need? Get the answers in writing if possible.
Request the treatment plan before session one. The plan should state the target, the session count, and the symptom measures that will be used to judge response. This document is what contractors review.
Keep your own records. Save the dates of every session, the symptom scores, and any correspondence about authorization. If a denial arrives, the appeal depends on a paper trail that patients often do not have.
Know the appeal path. A denial can be appealed through the Medicare appeals process, and Medicare Advantage plans have their own reconsideration steps. Deadlines are short, often 60 days for a redetermination, so act quickly.
Limitations and what the evidence cannot settle
Coverage rules change through contractor policy and plan formularies, and the specifics vary by region and plan year. This explainer describes the stable structure of Medicare coverage for TMS, not the current status of any individual plan. Patients should verify details with their contractor or plan before treatment.
The clinical evidence for TMS in treatment-resistant depression is substantial, but it is not a cure and response rates are imperfect. Remission is achievable for a meaningful share of patients, yet a substantial minority does not respond, and relapse after a successful course is common. Coverage rules reflect that uncertainty by requiring documented treatment resistance rather than offering TMS as a first-line option.
What cannot be concluded from coverage policy alone: whether TMS will work for a specific person, how many sessions that person will need, or whether maintenance will be covered. Those are clinical and contractual questions that require a treating clinician and a benefits check, not a general explainer. The honest bottom line is that Medicare covers TMS for a narrow, well-documented population, and the paperwork is as decisive as the diagnosis.